Skip to content
Home/Companies/Life Science Tools & Biologic Services/Xpress Biologics

Xpress Biologics

Life Science Tools & Biologic Services·Belgium·Exited 2022·Held 1yr
Entry
2021
Hold
1yr
Exit
2022

Who owns Xpress Biologics?

Xpress Biologics was owned by ARCHIMED through MED III (2021 vintage) from 2021 to 2022, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-04-21

ARCHIMED
Investor
ARCHIMED
MED III · 2021 · Buyout

Key facts

HQBelgium
SectorLife Science Tools & Biologic Services
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2022

More from MED III

Other portfolio companies in the same fund.

BioVendor Group
Active
MedTechCzech Republic· 2025
DermaPharm
DermaPharm
Active
HealthTechDenmark· 2025
Natus Sensory
Natus Sensory
Active
MedTechUS· 2022
PlasmidFactory
PlasmidFactory
Active
BiotechGermany· 2022
Title21 Health Solutions
Title21 Health Solutions
Active
HealthTechUS· 2022
Aliri
Aliri
Active
PharmaUS· 2021

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Xpress Biologics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Xpress Biologics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue